Table I.
Clinical and Microbiological Data of Six Cytomegalovirus (CMV)‐Seropositive Patients With CMV DNA Detected in the Lower Respiratory Tract
| Underlying disease | CMV/HHV‐6 DNA in LRT copies/mla | CMV DNA in plasma copies/ml | Respiratory virusesb | Bacterial and fungal culturesc |
|---|---|---|---|---|
| Cystic fibrosis | 334/2,350 | NDd | ND | S. aureus |
| Atelectasis | 182/ND | 123 | ND | Negative |
| Cystic fibrosis | 27/126 | ND | Rhinovirus | S. aureus |
| Atelectasis | 425/ND | 18 | ND | Negative |
| Bronchiolitis obliterans | 69/ND | ND | ND | Negative |
| Atelectasis | 1,285/ND | ND | Bocavirus | Negative |
a
CMV DNA load was quantitated by real‐time PCR with the Abbott CMV PCR kit. Detection and quantitation of human herpesvirus‐6 was performed by real‐time PCR (Realquality RS‐HHV6; AB Analitica, Padova, Italy).
b
Detection of respiratory viruses was performed by multiplex PCR using the RVP Fast assay (Luminex Molecular Diagnostics Inc., Toronto, Canada).
c
Growth of ≥104 or ≥105 CFU/ml of bacterial or fungal species in bronchoaspitates or bronchoalveolar lavages respectively was considered significant.
d
Not detected.